Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

Company Overview

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners. Adaptive also develops T-cell receptor (TCR) discovery services to support the discovery and development of novel TCR-based therapeutics. Its offerings span research services, clinical diagnostics, and collaborative programs with leading drug developers to advance immune-driven medicine.

Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies maintains research and operations facilities in North America and Europe. The company collaborates with global technology and life sciences organizations, including a strategic partnership with Microsoft to apply machine learning to immune data. Adaptive’s platform has been utilized in oncology, autoimmune and infectious disease research across multiple continents.

Adaptive Biotechnologies is led by co-founder and CEO Chad Robins, under whose guidance the firm continues to expand its molecular profiling capabilities and build a world-class immune medicine business.

Key Stats

• Today's Range: $12.98 to $14.98
• 50-Day Range: $12.41 to $16.46
• 52-Week Range: $8.38 to $20.76
• Volume: 1.57 million shs
• Average Volume: 1.94 million shs
• Market Capitalization: $2.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.43
• Consensus Rating: Moderate Buy

Adaptive Biotechnologies Stock Analysis - MarketRank™

Adaptive Biotechnologies scored higher than 63% of companies evaluated by MarketBeat, and ranked 240th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Adaptive Biotechnologies has a consensus price target of $19.43, representing about 34.2% upside from its current price of $14.47.

Amount of Analyst Coverage

Adaptive Biotechnologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.50) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adaptive Biotechnologies is -35.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adaptive Biotechnologies is -35.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adaptive Biotechnologies has a P/B Ratio of 9.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.93% of the float of Adaptive Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.41.

Change versus previous month

Short interest in Adaptive Biotechnologies has recently decreased by 0.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adaptive Biotechnologies does not currently pay a dividend.

Dividend Growth

Adaptive Biotechnologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.59

News Sentiment

Adaptive Biotechnologies has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Adaptive Biotechnologies this week, compared to 5 articles on an average week.

MarketBeat Follows

3 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,153,000.00 in company stock.

Percentage Held by Insiders

5.70% of the stock of Adaptive Biotechnologies is held by insiders.

Percentage Held by Institutions

99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADPT Stock Analysis - Frequently Asked Questions

How have ADPT shares performed this year?

Adaptive Biotechnologies' stock was trading at $16.24 at the start of the year. Since then, ADPT shares have decreased by 10.9% and is now trading at $14.4730.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies's quarterly revenue was up 35.1% on a year-over-year basis.
Read the conference call transcript.

When did Adaptive Biotechnologies IPO?

Adaptive Biotechnologies (ADPT) raised $278 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $18.00-$19.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Who are Adaptive Biotechnologies' major shareholders?

Top institutional investors of Adaptive Biotechnologies include Principal Financial Group Inc. (1.07%), Sumitomo Mitsui Trust Group Inc. (1.04%), Capricorn Fund Managers Ltd (0.84%) and Hillsdale Investment Management Inc. (0.39%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Tycho Peterson, Susan Bobulsky, Julie Rubinstein, Sharon Benzeno, Francis Lo, Kyle Piskel, Nitin Sood, Peter M Neupert, Stacy L Taylor, Michelle Renee Griffin and Robert Hershberg.
View institutional ownership trends.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADPT
• CIK: 1478320
• Web: www.constructionpartners.net
• Phone: (206) 659-0067
• Fax: 206-659-0667
• Employees: 790
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Adaptive Biotechnologies: $19.43
• High Price Target: $22.00
• Low Price Target: $15.00
• Potential Upside/Downside: +38.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.50 million
• Net Margins: -21.48%
• Pretax Margin: -21.47%
• Return on Equity: -46.68%
• Return on Assets: -18.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.34
• Quick Ratio: 3.23

Sales & Book Value

• Annual Sales: $276.98 million
• Price / Sales: 8.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.47 per share
• Price / Book: 9.52

Miscellaneous

• Outstanding Shares: 159,760,000
• Free Float: 150,655,000
• Market Cap: $2.24 billion
• Optionable: Optionable
• Beta: 2.16